UK Markets closed

GlaxoSmithKline plc (GSK.L)


LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,708.50-13.50 (-0.78%)
At close: 4:35PM BST
Full screen
Previous close1,722.00
Open1,720.00
Bid1,684.50 x 175400
Ask1,720.00 x 417900
Day's range1,708.50 - 1,721.50
52-week range1,446.50 - 1,745.56
Volume4,340,832
Avg. volume9,025,728
Market cap83.47B
Beta1.22
PE ratio (TTM)50.10
EPS (TTM)34.1
Earnings date26 Jul 2017
Dividend & yield1.00 (4.65%)
Ex-dividend date2017-02-23
1y target est1,789.77
  • Fool.co.ukyesterday

    You can achieve financial independence easily by using buckets

    This one tip could trick you into saving more.

  • New GSK chief kicks off shake-up with Maximuscle sale
    Sky News3 days ago

    New GSK chief kicks off shake-up with Maximuscle sale

    The new chief executive of GlaxoSmithKline (Amsterdam: GO8.AS - news) (GSK) is kicking off her tenure with a move to offload the division which owns Maximuscle, a nutritional products brand favoured by elite athletes. Sky News has learnt that Emma Walmsley, who replaced Sir Andrew Witty at the helm of Britain's biggest drugs manufacturer earlier this year, is pursuing a sale of MaxiNutrition, which was bought in 2010 for £162m. MaxiNutrition, which makes a range of sports nutrition supplements, has partnership deals with England Rugby and teams including London Wasps.

  • GSK's new CEO aims to divest sports nutrition brand: sources
    Reuters3 days ago

    GSK's new CEO aims to divest sports nutrition brand: sources

    GlaxoSmithKline Plc's new Chief Executive Officer Emma Walmsley is shaking up the British drugmaker's portfolio of smaller products with plans to divest its MaxiNutrition sports nutrition brand, two people familiar with the matter said on Thursday. GSK bought the business, which makes protein bars, drinks and powders, for 162 million pounds ($205 million) in 2010 under previous CEO Andrew Witty. The original acquisition was seen as complementing GSK's Lucozade sports drinks.